594P The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy

• DOI: 10.1016/j.annonc.2023.09.1785
• Publication Date: 2023-10-20T12:26:34Z
• Authors: N. Izawa; T. Kudo; S. Yuki; M. Nakamura; D. Manaka; Y. Kumekawa; T. Mine; T. Okuno; H. Oda; T. Sagawa; T. Kawai; T. Shingai; M. Kotaka; K. Kobayashi; Y. Kagawa; H. Satake; M. Takeuchi; W. Ichikawa; M. Fujii; Y. Sunakawa
• Keywords: Regimen; Chemotherapy regimen; Progression-free survival